Polyclonal Antibody to Amyloid Beta Precursor Protein Binding Protein B3 (APBB3)
| Code | Size | Price |
|---|
| PAC959Ra01-20ul | 20ul | £92.00 |
Quantity:
| PAC959Ra01-100ul | 100ul | £173.00 |
Quantity:
| PAC959Ra01-200ul | 200ul | £234.00 |
Quantity:
| PAC959Ra01-1ml | 1ml | £539.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Rat
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
APB-B3; SRA; FE65L2; FE65-L2; Fe65L2 isoform 484; Alzheimer's beta-amyloid interaction protein; Amyloid beta (A4) protein-binding, family B, member 3, isoform CRA_g
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
Amyloid Beta Precursor Protein Binding Protein B3
Reactivity:
Hu;Mu;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;<br/>Immunohistochemistry: 5-20ug/mL;<br/>Immunocytochemistry: 5-20ug/mL;<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Amyloid Beta Precursor Protein Binding Protein B3 (APBB3) | RPC959Ra01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||